AbbVie Inc. (ABBV) vs Ørsted A/S (DOGEF)

AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.

Ørsted A/S is a publicly traded company active in electricity, gas, LNG, energy infrastructure, renewable power, or regulated utility services. Its shares give investors exposure to those activities. The company's performance is influenced by revenue growth, margins, competitive position, capital allocation, regulation, currency movements where relevant, and broader economic and market conditions.